HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated…
/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the.
/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and.
NEW YORK, Aug. 9, 2023 /PRNewswire/ Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business.